# Xcyte Therapies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xcyte-therapies

- Industry: Biotechnology
- Headquarters: Seattle, US
- Total disclosed funding: $28M
- Latest round: Series D (Aug 16, 2000)
- Investors on record: 10

## About

Xcyte Therapies, Inc. is a US-based company that operates as a developer of therapeutic products that enhance the body’s natural immune responses to treat cancer, infectious diseases, and other medical conditions associated with weakened immune systems.

## Funding rounds

- Series D, Aug 16, 2000, $28M — Alta Partners, ARCH Venture Partners, Sprout Group, Fluke Venture Partners, Tredegar Corporation, Vector Fund Management, MPM BioImpact, Vulcan, Falcon Technology Partners, MGN Opportunity Group

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series D
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series D
- Sprout Group (https://capitalatlas.ai/funds/sprout-group) — Series D
- Fluke Venture Partners (https://capitalatlas.ai/funds/fluke-venture-partners) — Series D
- Tredegar Corporation — Series D
- Vector Fund Management (https://capitalatlas.ai/funds/vector-fund-management) — Series D
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series D
- Vulcan (https://capitalatlas.ai/funds/vulcan) — Series D
- Falcon Technology Partners (https://capitalatlas.ai/funds/falcon-technology-partners) — Series D
- MGN Opportunity Group — Series D